218. アルポート症候群 Disease details / Clinical trials / Drug dev / DR info

ACE I, ATA II and statins
   Mario Negri Institute for Pharmacological Research
      2004   Phase 2   NCT00309257   Italy
ACE-inhibitor
   University Hospital Goettingen
      1995   -   NCT02378805   Germany
Angiotensin
   Guangzhou Women and Children’s Medical Center, Guangzhou Medical University
      2025   -   ChiCTR2500097229   China
   University Hospital Goettingen
      1995   -   NCT02378805   Germany
Atrasentan
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
Bardoxolone methyl
   Reata Pharmaceuticals, Inc
      2018   -   JPRN-UMIN000032448   Japan,North America,Australia,Europe
   Reata Pharmaceuticals, Inc.
      2019   Phase 3   JPRN-UMIN000039943   Japan,North America,Australia,Europe
      2018   Phase 2;Phase 3   EUCTR2016-004395-22-GB   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2016-004395-22-ES   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-FR   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-DE   Australia;Canada;France;Germany;Spain;United Kingdom;United States
   Reata, a wholly owned subsidiary of Biogen
      2019   Phase 3   NCT03749447   Australia;France;Japan;Puerto Rico;Spain;United States
      2017   Phase 2/Phase 3   NCT03019185   Australia;Canada;France;Germany;Japan;Puerto Rico;Spain;United Kingdom;United States
Benazepril
   Shanghai Children's Hospital
      2020   -   ChiCTR2000036799   China
Benazepril hydrochloride 10 milligram (MG) TAB
   Shanghai Children's Hospital
      2021   Phase 2   NCT04937907   China
Benazepril, valsartan and fluvastatin
   Mario Negri Institute for Pharmacological Research
      2004   Phase 2   NCT00309257   Italy
Dapagliflozin
   Guangzhou Women and Children’s Medical Center, Guangzhou Medical University
      2025   -   ChiCTR2500097229   China
   University Hospital Goettingen
      2024   Phase 3   NCT05944016   Germany
Dapagliflozin 10MG TAB
   Nanjing University School of Medicine
      2023   -   NCT06226896   China
Delix
   University Medical Center Göttingen
      2012   Phase 3   EUCTR2010-024300-10-DE   Germany
ELX-02
   Eloxx Pharmaceuticals, Inc.
      2022   Phase 2   NCT05448755   Australia;United Kingdom
Finerenone
   peking university first hospital
      2024   Phase 1   ChiCTR2400079455   China
Henagliflozin
   peking university first hospital
      2024   Phase 1   ChiCTR2400079455   China
HUC-MSC
   Guangzhou Women and Children's Medical Center
      2025   Phase 2/Phase 3   NCT06731192   -
Hydroxychloroquine
   Shanghai Children's Hospital
      2020   -   ChiCTR2000036799   China
Hydroxychloroquine sulfate 100 milligram (MG) TAB
   Shanghai Children's Hospital
      2021   Phase 2   NCT04937907   China
Lademirsen
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States
   Genzyme, a Sanofi Company
      2019   Phase 2   NCT02855268   Australia;Canada;China;France;Germany;Spain;United Kingdom;United States
Metformin
   Peking University First Hospital
      2023   Phase 4   NCT05655728   -
Paricalcitol
   University Hospital Goettingen
      1995   -   NCT02378805   Germany
R3r01
   River 3 Renal Corp.
      2022   Phase 2   NCT05267262   Belgium;France;Germany;Netherlands;United Kingdom;United States
   River 3 Renal, Corporation
      2022   Phase 2   EUCTR2021-004192-13-NL   Belgium;France;Germany;Netherlands;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004192-13-BE   Belgium;France;Germany;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2021-004192-13-FR   Belgium;France;Germany;Netherlands;United Kingdom;United States
Ramipril
   Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
      2012   Phase 3   NCT01485978   Germany
   University Medical Center Göttingen
      2012   Phase 3   EUCTR2010-024300-10-DE   Germany
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2022   -   NCT05133050   China
RE-021
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
RG-012
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States
   Regulus Therapeutics Inc.
      2016   Phase 2   EUCTR2016-002181-32-GB   Australia;Canada;France;Germany;Spain;United Kingdom;United States
RG012
   Genzyme, a Sanofi Company
      2017   Phase 1   NCT03373786   United States
RTA 402
   Reata Pharmaceuticals, Inc.
      2018   Phase 2;Phase 3   EUCTR2016-004395-22-GB   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2016-004395-22-ES   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-FR   Australia;Canada;France;Germany;Spain;United Kingdom;United States
      2017   Phase 2;Phase 3   EUCTR2016-004395-22-DE   Australia;Canada;France;Germany;Spain;United Kingdom;United States
SAR339375
   Genzyme Corporation
      2020   Phase 2   EUCTR2019-004394-10-DE   Australia;China;France;Germany;Spain;United Kingdom;United States
   Genzyme, a Sanofi Company
      2019   Phase 2   NCT02855268   Australia;Canada;China;France;Germany;Spain;United Kingdom;United States
Setanaxib
   Calliditas Therapeutics AB
      2023   Phase 1/Phase 2   NCT06274489   Austria;Czechia;France;Lithuania;Slovakia;Spain;United Kingdom
SGLT2 inhibitor
   University Hospital Goettingen
      1995   -   NCT02378805   Germany
Sparsentan
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   NCT05003986   Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Spironolactone or finerenone
   University Hospital Goettingen
      1995   -   NCT02378805   Germany
Vonafexor
   Enyo Pharma
      2024   Phase 2   NCT06425055   France;Germany;Spain;United States